Abstract:Background: Chronic use of mu-opioid receptor agonists paradoxically causes both hyperalgesia and the loss of analgesic efficacy. Opioid treatment increases presynaptic N-methyl-d-aspartate receptor activity to potentiate nociceptive input to spinal dorsal horn neurons. However, the mechanism responsible for this opioid- induced activation of presynaptic N-methyl-d-aspartate receptors remains unclear. alpha 2 delta-1, formerly known as a calcium channel subunit, interacts with N-methyl-d-aspartate receptors and is primarily expressed at presynaptic terminals. This study tested the hypothesis that alpha 2 delta-1-bound N-methyl-d-aspartate receptors contribute to presynaptic N-methyl-d-aspartate receptor hyperactivity associated with opioid-induced hyperalgesia and analgesic tolerance. Methods: Rats (5 mg/kg) and wild-type and alpha 2 delta-1-knockout mice (10 mg/kg) were treated intraperitoneally with morphine twice/day for 8 consecutive days, and nociceptive thresholds were examined. Presynaptic N-methyl-d-aspartate receptor activity was recorded in spinal cord slices. Coimmunoprecipitation was performed to examine protein-protein interactions. Results: Chronic morphine treatment in rats increased alpha 2 delta-1 protein amounts in the dorsal root ganglion and spinal cord. Chronic morphine exposure also increased the physical interaction between alpha 2 delta-1 and N-methyl-d-aspartate receptors by 1.5 +/- 0.3 fold (means +/- SD, P = 0.009, n = 6) and the prevalence of alpha 2 delta-1-bound N-methyl-d-aspartate receptors at spinal cord synapses. Inhibiting alpha 2 delta-1 with gabapentin or genetic knockout of alpha 2 delta-1 abolished the increase in presynaptic N-methyl-d-aspartate receptor activity in the spinal dorsal horn induced by morphine treatment. Furthermore, uncoupling the alpha 2 delta-1-Nmethyl- d-aspartate receptor interaction with an alpha 2 delta-1 C terminus-interfering peptide fully reversed morphine-induced tonic activation of N-methyl-d-aspartate receptors at the central terminal of primary afferents. Finally, intraperitoneal injection of gabapentin or intrathecal injection of an alpha 2 delta-1 C terminus-interfering peptide or alpha 2 delta-1 genetic knockout abolished the mechanical and thermal hyperalgesia induced by chronic morphine exposure and largely preserved morphine's analgesic effect during 8 days of morphine treatment. Conclusions: alpha 2 delta-1-Bound N-methyl-d-aspartate receptors contribute to opioid-induced hyperalgesia and tolerance by augmenting presynaptic N-methyl-d-aspartate receptor expression and activity at the spinal cord level.

Increased Methylation of the MOR Gene Proximal Promoter in Primary Sensory Neurons Plays a Crucial Role in the Decreased Analgesic Effect of Opioids in Neuropathic Pain

MeCP2 Epigenetic Silencing of Oprm1 Gene in Primary Sensory Neurons Under Neuropathic Pain Conditions

Nerve Injury–induced Epigenetic Silencing of Opioid Receptors Controlled by DNMT3a in Primary Afferent Neurons

Neuron-restrictive Silencer Factor–mediated Downregulation of Μ-Opioid Receptor Contributes to the Reduced Morphine Analgesia in Bone Cancer Pain

Acute Morphine Induces Matrix Metalloproteinase-9 Up-Regulation in Primary Sensory Neurons to Mask Opioid-Induced Analgesia in Mice

Mu-Opioid Receptor (MOR) Dependence of Pain in Chemotherapy-Induced Peripheral Neuropathy

Oligomerization of MrgC11 and Μ-Opioid Receptors in Sensory Neurons Enhances Morphine Analgesia.

Activation of CXCL10/CXCR3 Signaling Attenuates Morphine Analgesia: Involvement of Gi Protein

Antisense oligonucleotide knockdown of mGlu₅ receptor attenuates the antinociceptive tolerance and up-regulated expression of spinal protein kinase C associated with chronic morphine treatment.

Peripheral axonal injury results in reduced mu opioid receptor pre- and post-synaptic action in the spinal cord

Mitogen‐activated protein kinase signaling mediates opioid‐induced presynaptic <scp>NMDA</scp> receptor activation and analgesic tolerance

Molecular mechanism and candidate biomarkers of morphine for analgesia and addiction effects

Α2δ-1–Boundn-methyl-d-aspartate Receptors Mediate Morphine-induced Hyperalgesia and Analgesic Tolerance by Potentiating Glutamatergic Input in Rodents

Comparative Pharmacological Profiles of Morphine and Oxycodone under a Neuropathic Pain-Like State in Mice: Evidence for Less Sensitivity to Morphine

Mitogen‐activated Protein Kinase Signaling Mediates Opioid‐induced Presynaptic NMDA Receptor Activation and Analgesic Tolerance

Inhibitory Effect of Spinal Mglu(5) Receptor Antisense Oligonucleotide on the Up-Regulated Expression of Spinal G Protein Associated with Chronic Morphine Treatment.

Synaptic Mechanism for Functional Synergism Between Δ- and Μ-Opioid Receptors

Pharmacological Modulation of the MIP-1 Family and Their Receptors Reduces Neuropathic Pain Symptoms and Influences Morphine Analgesia: Evidence from a Mouse Model

Increased Glutamate Synaptic Transmission in the Nucleus Raphe Magnus Neurons from Morphine-Tolerant Rats

Blockade of Peripheral Nociceptive Signal Input Relieves the Formation of Spinal Central Sensitization and Retains Morphine Efficacy in a Neuropathic Pain Rat Model.

The mechanism of μ-opioid receptor (MOR)-TRPV1 crosstalk in TRPV1 activation involves morphine anti-nociception, tolerance and dependence